- Home
- RENE vs ACRV Comparison
RENE vs ACRV Comparison
Compare RENE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENE
- ACRV
- Stock Information
- Founded
- RENE 2021
- ACRV 2018
- Country
- RENE United States
- ACRV United States
- Employees
- RENE N/A
- ACRV N/A
- Industry
- RENE Blank Checks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- RENE Finance
- ACRV Health Care
- Exchange
- RENE Nasdaq
- ACRV Nasdaq
- Market Cap
- RENE 248.9M
- ACRV 247.8M
- IPO Year
- RENE 2022
- ACRV 2022
- Fundamental
- Price
- RENE $11.62
- ACRV $6.44
- Analyst Decision
- RENE
- ACRV Strong Buy
- Analyst Count
- RENE 0
- ACRV 5
- Target Price
- RENE N/A
- ACRV $22.40
- AVG Volume (30 Days)
- RENE 218.7K
- ACRV 46.9K
- Earning Date
- RENE 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- RENE N/A
- ACRV N/A
- EPS Growth
- RENE 42.92
- ACRV N/A
- EPS
- RENE 0.43
- ACRV N/A
- Revenue
- RENE N/A
- ACRV N/A
- Revenue This Year
- RENE N/A
- ACRV N/A
- Revenue Next Year
- RENE N/A
- ACRV N/A
- P/E Ratio
- RENE $26.81
- ACRV N/A
- Revenue Growth
- RENE N/A
- ACRV N/A
- 52 Week Low
- RENE $10.88
- ACRV $3.19
- 52 Week High
- RENE $11.67
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- RENE 59.82
- ACRV 31.95
- Support Level
- RENE $11.62
- ACRV $6.11
- Resistance Level
- RENE $11.67
- ACRV $8.35
- Average True Range (ATR)
- RENE 0.01
- ACRV 0.48
- MACD
- RENE -0.00
- ACRV -0.23
- Stochastic Oscillator
- RENE 70.59
- ACRV 12.55
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.